Human papillomavirus type-specific persistence and recurrence after treatment for cervical dysplasia

Journal of Medical Virology

Volumn 86, Issue 4, 2014, Pages 634-641

  Söderlund Strand, Anna ^a   Kjellberg, Lennart ^b   Dillner, Joakim ^c  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cervical screening; HPV genotyping; Loop electrosurgical excision procedure (LEEP)

Indexed keywords

CERVICAL SCREENING; HPV GENOTYPING; LOOP ELECTROSURGICAL EXCISION PROCEDURE (LEEP);

ADULT; ALPHAPAPILLOMAVIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; DNA, VIRAL; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTIONS; RECURRENCE; UTERINE CERVICAL DYSPLASIA; VAGINAL SMEARS; YOUNG ADULT;

EID: 84893782444     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23806     Document Type: Article

References (38)

1. Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, Koliopoulos G, Naucler P, Sankaranarayanan R, Peto J. 2012. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 30:F88-F99.
2. Bae JH, Kim CJ, Park TC, Namkoong SE, Park JS. 2007. Persistence of human papillomavirus as a predictor for treatment failure after loop electrosurgical excision procedure. Int J Gynecol Cancer 17:1271-1277.
3. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV. 1995. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst 87:796-802.
4. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V. 2009. A review of human carcinogens-Part B: Biological agents. Lancet Oncol 10:321-322.
5. Chua KL, Hjerpe A. 1997. Human papillomavirus analysis as a prognostic marker following conization of the cervix uteri. Gynecol Oncol 66:108-113.
6. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. 2005. Human papillomavirus genotype distribution in low-grade cervical lesions: Comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 14:1157-1164.
7. Costa S, De Simone P, Venturoli S, Cricca M, Zerbini ML, Musiani M, Terzano P, Santini D, Cristiani P, Syrjanen S, Syrjanen K. 2003. Factors predicting human papillomavirus clearance in cervical intraepithelial neoplasia lesions treated by conization. Gynecol Oncol 90:358-365.
8. Coupe VM, Berkhof J, Verheijen RH, Meijer CJ. 2007. Cost-effectiveness of human papillomavirus testing after treatment for cervical intraepithelial neoplasia. BJOG 114:416-424.
9. de Roda Husman AM, Snijders PJ, Stel HV, van den Brule AJ, Meijer CJ, Walboomers JM. 1995a. Processing of long-stored archival cervical smears for human papillomavirus detection by the polymerase chain reaction. Br J Cancer 72:412-417.
10. de Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ. 1995b. The use of general primers GP5 and GP6 elongated at their 3′-ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol 76:1057-1062.
11. Distefano AL, Picconi MA, Alonio LV, Dalbert D, Mural J, Bartt O, Bazan G, Cervantes G, Lizano M, Carranca AG, Teyssie A. 1998. Persistence of human papillomavirus DNA in cervical lesions after treatment with diathermic large loop excision. Infect Dis Obstet Gynecol 6:214-219.
12. Elfgren K, Jacobs M, Walboomers JM, Meijer CJ, Dillner J. 2002. Rate of human papillomavirus clearance after treatment of cervical intraepithelial neoplasia. Obstet Gynecol 100:965-971.
13. Forslund O, Hansson BG, Bjerre B. 1994. Typing of human papillomaviruses by consensus polymerase chain reaction and a non-radioactive reverse dot blot hybridization. J Virol Methods 49:129-139.
14. Gonzalez DI Jr, Zahn CM, Retzloff MG, Moore WF, Kost ER, Snyder RR. 2001. Recurrence of dysplasia after loop electrosurgical excision procedures with long-term follow-up. Am J Obstet Gynecol 184:315-321.
15. Heymans J, Benoy IH, Poppe W, Depuydt CE. 2011. Type-specific HPV geno-typing improves detection of recurrent high-grade cervical neoplasia after conisation. Int J Cancer 129:903-909.
16. Jeong NH, Lee NW, Kim HJ, Kim T, Lee KW. 2009. High-risk human papillomavirus testing for monitoring patients treated for high-grade cervical intraepithelial neoplasia. J Obstet Gynaecol Res 35:706-711.
17. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK. 2013. Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: Performance of HPV and Pap cotesting in posttreatment management. J Low Genit Tract Dis 17:S78-S84.
18. Kim YT, Lee JM, Hur SY, Cho CH, Kim SC, Kang SB. 2010. Clearance of human papillomavirus infection after successful conization in patients with cervical intraepithelial neoplasia. Int J Cancer 126:1903-1909.
19. Kjaer SK, van den Brule AJ, Bock JE, Poll PA, Engholm G, Sherman ME, Walboomers JM, Meijer CJ. 1996. Human papillomavirus-The most significant risk determinant of cervical intraepithelial neoplasia. Int J Cancer 65:601-606.
20. Kjaer SK, van den Brule AJ, Paull G, Svare EI, Sherman ME, Thomsen BL, Suntum M, Bock JE, Poll PA, Meijer CJ. 2002. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: Population based prospective follow up study. BMJ 325:572.
21. Kjellberg L, Wang Z, Wiklund F, Edlund K, Angstrom T, Lenner P, Sjoberg I, Hallmans G, Wallin KL, Sapp M, Schiller J, Wadell G, Mahlck CG, Dillner J. 1999. Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: A population-based case-control study. J Gen Virol 80:391-398.
22. Kjellberg L, Wadell G, Bergman F, Isaksson M, Angstrom T, Dillner J. 2000. Regular disappearance of the human papillomavirus genome after conization of cervical dysplasia by carbon dioxide laser. Am J Obstet Gynecol 183:1238-1242.
23. Kocken M, Helmerhorst TJ, Berkhof J, Louwers JA, Nobbenhuis MA, Bais AG, Hogewoning CJ, Zaal A, Verheijen RH, Snijders PJ, Meijer CJ. 2011. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: A long-term multi-cohort study. Lancet Oncol 12:441-450.
24. Kocken M, Uijterwaal MH, de Vries AL, Berkhof J, Ket JC, Helmerhorst TJ, Meijer CJ. 2012. High-risk human papillomavirus testing versus cytology in predicting post-treatment disease in women treated for high-grade cervical disease: A systematic review and meta-analysis. Gynecol Oncol 125:500-507.
25. Koss LG, editor. 1979. Diagnostic cytology and its histopathologic basis. 3rd edition. Philadelphia, PA: Lippincott.
26. Kreimer AR, Katki HA, Schiffman M, Wheeler CM, Castle PE. 2007. Viral determinants of human papillomavirus persistence following loop electrical excision procedure treatment for cervical intraepithelial neoplasia grade 2 or 3. Cancer Epidemiol Biomarkers Prev 16:11-16.
27. Kreimer AR, Schiffman M, Herrero R, Hildesheim A, Gonzalez P, Burk RD, Porras C, Sherman ME, Demuth F, Cheung L, Bratti C, Cecilia Rodriguez A. 2012. Long-term risk of recurrent cervical human papillomavirus infection and precancer and cancer following excisional treatment. Int J Cancer 131:211-218.
28. Kucera E, Sliutz G, Czerwenka K, Breitenecker G, Leodolter S, Reinthaller A. 2001. Is high-risk human papillomavirus infection associated with cervical intraepithelial neoplasia eliminated after conization by large-loop excision of the transformation zone? Eur J Obstet Gynecol Reprod Biol 100:72-76.
29. Nagai Y, Maehama T, Asato T, Kanazawa K. 2000. Persistence of human papillomavirus infection after therapeutic conization for CIN 3: Is it an alarm for disease recurrence? Gynecol Oncol 79:294-299.
30. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Hansson BG, Rylander E, Dillner J. 2007. HPV type-specific risks of high-grade CIN during 4 years of follow-up: A population-based prospective study. Br J Cancer 97:129-132.
31. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, Rozendaal L, Remmink AJ, Risse EK, van der Linden HC, Voorhorst FJ, Kenemans P, Meijer CJ. 1999. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: A prospective study. Lancet 354:20-25.
32. Paraskevaidis E, Arbyn M, Sotiriadis A, Diakomanolis E, Martin-Hirsch P, Koliopoulos G, Makrydimas G, Tofoski J, Roukos DH. 2004. The role of HPV DNA testing in the follow-up period after treatment for CIN: A systematic review of the literature. Cancer Treat Rev 30:205-211.
33. Russell D, Sambrook J, editors. 2001. Molecular cloning: A laboratory manual. 3rd edition. New York, NY: Cold Spring Harbor Laboratory Press, pp 6.4-6.11.
34. Soderlund-Strand A, Rymark P, Andersson P, Dillner J, Dillner L. 2005. Comparison between the hybrid capture II test and a PCR-based human papillomavirus detection method for diagnosis and posttreatment follow-up of cervical intraepithelial neoplasia. J Clin Microbiol 43:3260-3266.
35. Tangtrakul S, Linasmita V, Israngura N, Srisupundit S, Bullangpoti S, Wilailak S. 2002. Detection of residual disease by cytology in patients with cervical intraepithelial neoplasia III post-large loop excision of the transformation zone. J Obstet Gynaecol Res 28:95-98.
36. Verguts J, Bronselaer B, Donders G, Arbyn M, Van Eldere J, Drijkoningen M, Poppe W. 2006. Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: The role of human papillomavirus testing and age at conisation. BJOG 113:1303-1307.
37. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12-19.
38. Zielinski GD, Rozendaal L, Voorhorst FJ, Berkhof J, Snijders PJ, Risse EJ, Runsink AP, de Schipper FA, Meijer CJ. 2003. HPV testing can reduce the number of follow-up visits in women treated for cervical 'intraepithelial neoplasia grade 3. Gynecol Oncol 91:67-73.